Before the Conclusion · BioStockEdge Editor's Note 001
Sources updated through October 24, 2026
On October 22, 2026, Moderna and Merck & Co. released detailed phase 3 clinical data for a personalized cancer vaccine: the trial had met its prespecified efficacy endpoints.
That day, Moderna's shares closed down 17.57%. They fell another 1.25% the next day, closing at $200.10.[1][5]
On October 24, a presentation at the European Society for Medical Oncology Congress (ESMO) added details on overall survival, safety, and the manufacturing process.[2][3]
The main efficacy numbers did not change. But the details help us understand the value and limits of this advance more accurately.
The same data may strengthen our confidence in a treatment while still falling short of supporting every valuation assumption built around it.
1. What exactly did this trial establish?
The vaccine is called intismeran autogene, also known as V940 or mRNA-4157. It is designed around the characteristics of each patient's own tumor, aiming to train the immune system to recognize cancer cells. It treats cancer that has already developed.[1]
The randomized, double-blind phase 3 trial, INTerpath-001, enrolled 1,137 patients whose stage IIB–IV cutaneous melanoma had been completely removed.[1]
After surgery, patients were randomly assigned 2:1 to the vaccine plus pembrolizumab or placebo plus pembrolizumab. Pembrolizumab is Keytruda, commonly called “K-drug” in Chinese.
The comparison asked: on top of existing immunotherapy, can adding the vaccine further reduce recurrence or death?
At a median follow-up of 24.6 months, the primary analysis produced a hazard ratio, or HR, of 0.58, with a 95% confidence interval of 0.45–0.75. The company described this as a 42% reduction in the relative hazard of recurrence or death.
The key endpoint of distant metastasis or death also showed statistically significant improvement: HR 0.62, with a 95% confidence interval of 0.45–0.85.[1]
But “a 42% reduction” does not mean 42% of patients were cured. An HR reflects relative event hazards during follow-up, rather than a proportion at one fixed time point.
The estimates at two years are more intuitive:
| Estimated outcome at two years | Vaccine combination group | Control group |
|---|---|---|
| Alive without recurrence | 82.2% | 70.0% |
| Alive without distant metastasis | 88.5% | 80.2% |
The first row differs by 12.2 percentage points. Put more simply: in two groups of 100 similar patients each, an estimated 12 more patients in the combination group would be alive without recurrence at two years. This is still not a permanent cure rate.[1]
Overall survival requires greater caution. The October 24 presentation reported a hazard ratio for death of 0.77, with a 95% confidence interval of 0.45–1.31. It had not met the prespecified threshold for statistical significance, and follow-up continues.[3]
The evidence for reducing recurrence has strengthened. Whether the treatment prolongs life remains unconfirmed.
2. Safety cannot be summed up as “no new signals”
The company reported no new safety signals. The full safety table disclosed at the meeting makes the costs of treatment more concrete:
| Safety measure | Vaccine combination group | Control group |
|---|---|---|
| Grade 3–5 adverse events, regardless of attribution | 23.6% | 20.3% |
| Grade 3–5 treatment-related adverse events | 14.2% | 13.4% |
| Adverse events leading to discontinuation of either study drug | 16.6% | 9.5% |
The safety-analysis populations were 755 and 380, respectively. “Treatment-related” covers the study treatment regimen and does not mean that every event was caused by the vaccine.[3]
The safety table also recorded adverse events resulting in death: 8 in the combination group and 0 in the control group. Investigators attributed none of them to the vaccine and attributed 2 to pembrolizumab.[3]
These are fatal adverse events in the safety table, not all deaths in the overall-survival analysis. Both the event counts and investigators' judgments of attribution must be retained accurately.
“No new safety signals” is an assessment of the safety pattern. It cannot replace reading the specific information on adverse events, discontinuation, and deaths.
3. Manufacturing success above 99%: who is in the denominator?
Another piece of information worth adding today concerns production and delivery.
In its official October 24 explanation, Moderna reported that personalized vaccine manufacturing succeeded for more than 99% of the 757 patients assigned to the vaccine combination group.[2]
This provides important feasibility evidence: products designed separately for each patient can be manufactured through standardized processes within a global phase 3 trial.
But the denominator matters.
The original presentation showed that 1,749 people were screened, of whom 302 did not enter randomization because of insufficient tumor samples. It also listed a median time to the first vaccine dose of 64 days.[3]
The manufacturing success rate above 99% therefore applies to patients who had passed screening and entered the vaccine group. It cannot simply be generalized to mean that every patient can successfully receive treatment.
The 64-day time-to-dose measure also cannot be equated directly with time spent manufacturing inside the factory.
These data turn manufacturing from an abstract concern into a process that can be assessed concretely. Will samples meet the requirements? Can patients begin treatment promptly? With wider use, what will happen to waiting times, costs, and capacity?
Manufacturing has feasibility evidence from a clinical trial. Commercial delivery still needs further validation.
4. The market may have expected more than this one trial
Understanding the market reaction also requires the timeline.
In August this year, the two companies had already announced that the phase 3 trial had met its primary and key secondary efficacy endpoints. October's disclosure supplied more detailed effect sizes and study information.[4]
In other words, some positive expectations may already have been reflected in the share price. That is a hypothesis to examine when analyzing the price response.
In its October 22 report, BioSpace cited analysis from BMO and other institutions: some investors had hoped the data would both demonstrate benefit in melanoma and increase confidence in success in other cancers. The report also discussed effect size, cost, and competition from immunotherapy given before surgery.[6]
These are sourced market interpretations, not an account of every seller's motives. Patient populations and treatment timing also differ between trials, so comparing HRs alone cannot establish which of two regimens is better.
Nevertheless, the discussion points to a valuation assumption worth examining:
How much of the previous price paid for a melanoma treatment, and how much paid for a platform that might expand across multiple cancers?
Even a positive melanoma trial validates only part of that commercial picture. The probability of success in other cancers requires evidence for each one.
The judgment can be divided into three levels:
| Level of judgment | Central question |
|---|---|
| Clinical value | How much do patients benefit, and what costs do they bear? |
| Commercial value | What scale of actual use can manufacturing, delivery, and payment systems support? |
| Stock valuation | How much expected future success is already reflected in the current price? |
A treatment can have clinical value while its commercial scale and share price still require their own evidence and assumptions.
The decline itself therefore neither proves that the vaccine lacks clinical value nor establishes that the market has unjustifiably punished the stock.
5. Why not choose only the most attractive number?
The same trial also offers reductions larger than 42%.
For example, an analysis of the follow-up period after six months reported a 58% reduction in the relative hazard of recurrence or death. Another analysis excluded participants who had not received at least one planned dose of vaccine or placebo and found a 49% reduction.[1][2]
These supplementary analyses have their uses, but they change the observation period or analysis population. The largest number cannot simply replace the prespecified overall primary analysis.
The wait for vaccine dosing, the development of an immune response, and early recurrence all deserve further study. A more pronounced later effect is not, by itself, sufficient to establish which mechanism caused the difference.
For a product that must be manufactured separately for every patient, whether patients can actually receive it promptly is itself part of the treatment regimen.
The next questions are clearer now: whether benefits against recurrence and metastasis persist, what overall survival ultimately shows, which patients benefit more, and whether the production process can translate into affordable, sustainable real-world use.
Regulatory review and trials in other cancers will separately address the scope of use and the platform's expansion.
These phase 3 results bring personalized cancer vaccines a step closer to clinical use. They also let us ask more specifically: which judgments has the new evidence changed, and which expectations still await testing?
This is Before the Conclusion.
What does a piece of news, a number, a product, or an apparently good result actually mean?
Source note: public information was checked through October 24, 2026, including company announcements, that day's official explanation, and publicly shared photographs of the original ESMO LBA1 presentation slides taken at the meeting. The trial data cutoff was June 30, 2026, with median follow-up of 24.6 months. Additional disclosure does not mean an additional round of follow-up. Share-price data are through the close of regular US trading on October 23.
Companies discussed: Moderna (NASDAQ: MRNA); Merck & Co. (NYSE: MRK).
References:
- Merck and Moderna: detailed phase 3 INTerpath-001 results, October 22, 2026.
- Moderna: “Recapping the Phase 3 INTerpath-001 Results,” October 24, 2026.
- Long GV. ESMO Congress 2026, LBA1, presented October 24, 2026. Collection of public photographs of the original slides taken at the meeting. Checks included the summary, safety overview, patient flow, and manufacturing and dosing information. Numbers were taken from the original presentation pages.
- Merck and Moderna: first announcement that INTerpath-001 met its efficacy endpoints, August 19, 2026.
- Stock Analysis: Moderna historical share prices.
- BioSpace: ESMO 2026 coverage, October 22, 2026, cited as the source of the analysts' views.
Corresponding English article: The Trial Met Its Endpoints. Moderna Fell 17%. What Was the Market Pricing? The Chinese source for this translation incorporates the additional disclosures made on October 24.